Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients

Satohiro Masuda, Shinji Uemoto, Maki Goto, Yasuhiro Fujimoto, Koichi Tanaka, Ken Ichi Inui

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

To clarify the clinical applicability of intestinal absorptive barriers, we have quantified messenger ribonucleic acid (mRNA) expression levels of multidrug resistance 1 (MDR1) protein and cytochrome P450 (CYP) 3A4 in intestinal biopsy specimens from 2 small-bowel transplant recipients. Postoperative immunosuppressive therapy was started with intravenous and oral administrations of tacrolimus and a small amount of steroids. The daily dosage of tacrolimus was modified mainly on the basis of trough levels. After confirmation that the enterocyte MDR1 level was decreasing, tacrolimus was administered via the oral route only. The mRNA levels in the biopsy specimens varied widely throughout the period. With high-dose steroid-pulse treatment, the enterocyte mRNA expression of CYP3A4, but not of MDR1, was markedly enhanced. The mRNA levels of MDR1, but not CYP3A4, correlated well with the concentration/oral dose ratio and the oral dosage of tacrolimus. The good progress after transplantation in both cases suggested that monitoring the change in expression of MDR1 mRNA in the graft intestine might be helpful for understanding the pharmacokinetic profile and determining when to change the route of tacrolimus administration in small-bowel transplant recipients.

Original languageEnglish
Pages (from-to)352-361
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume75
Issue number4
DOIs
Publication statusPublished - Apr 1 2004
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients'. Together they form a unique fingerprint.

  • Cite this